Terapie anticorpali first-in-class (ADC e bispecifici) contro l'evasione immunitaria dei tumori.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Pre Seed Adaptam Therapeutics closed a €3 million pre-seed led by Criteria Bio Ventures for cancer immunotherapy. | $3.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.